As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/27/22  Cell MedX Corp.                   8-K:5,9     4/25/22   12:188K                                   Empire Stock Transf… Inc

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Cell Medx Corp. - Form 8-K SEC Filing               HTML     21K 
 2: EX-99.1     Press Release                                       HTML     12K 
 7: R1          Document and Entity Information                     HTML     41K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- cmxc-20220425_htm                   XML     12K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.DEF  XBRL Definitions -- cmxc-20220425_def                XML     10K 
 4: EX-101.LAB  XBRL Labels -- cmxc-20220425_lab                     XML     40K 
 5: EX-101.PRE  XBRL Presentations -- cmxc-20220425_pre              XML     27K 
 6: EX-101.SCH  XBRL Schema -- cmxc-20220425                         XSD     52K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               10±    16K 
12: ZIP         XBRL Zipped Folder -- 0001393905-22-000125-xbrl      Zip     11K 

 i 0001493712  i false 0001493712 2022-04-25 2022-04-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   i April 25, 2022

 

 i CELL MEDX CORP.

(Exact name of registrant as specified in its charter)

 

i NV	i 000-54500	i 38-3939625
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
i 123 W. Nye Ln, Suite 446  i Carson City,  i NV		i 89706
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code		( i 844)  i 238-2692

 

n/a

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

 i ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 i ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

 i ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   i ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

---

1

---

 

ITEM 5.02DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS 

 

On April 25, 2022, the board of directors of Cell MedX Corp. (the “Company”) unanimously resolved to increase the number of directors of the Company to six directors and to appoint Mr. Dwayne Yaretz as a director to fill the vacancy created by the increase in the number of directors. In addition, Mr. Yaretz was appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who resigned from his position as CEO of the Company on April 25, 2022. Mr. McEnulty will continue to serve on the Company’s board of directors.

 

Mr. Yaretz’ experience spans many industries including the development of industrial and medical imaging devices. He has aided in the re-structure of numerous companies by identifying and recruiting key personnel, enhancing the management team, capitalization, and maximizing business and sales opportunities. In the past, Mr. Yaretz has acted as a director, and held various top management positions, including CEO, CFO and president, with both private and public companies.

 

There is no family relationship among the directors. There are currently no compensation arrangements with Mr. Yaretz for acting as a member of the board of directors, or as the CEO.

 

A copy of the Company’s news release regarding the appointment of Mr. Yaretz and resignation of Mr. McEnulty is attached as Exhibit 99.1 hereto.

 

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS. 

 

(d)  Exhibits

 

The following exhibits are provided with this Current Report:

 

Exhibit Number	Description of Exhibit
99.1	News Release dated April 27, 2022.

 

 

 

 

 

 

 

 

 

 

---

2

---

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	CELL MEDX CORP.
Date:  April 27, 2022
	By: /s/ Joao (John) da Costa
	Joao (John) da Costa,
	Chief Operating Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

3